We examined the benefits of short linear α-helical antimicrobial peptides (AMPs) invented in our laboratory for treating bone infection and preventing microbial biofilm formation on model implants due to causative microorganisms of osteomyelitis. For this purpose, we introduced a model of induced osteomyelitis that utilizes human femur heads obtained from the hospital after their replacement with artificial prostheses. We found that the focus of the infection set up in the spongy part of this bone treated with AMP-loaded calcium phosphate cement was eradicated much more effectively than was the focus treated with antibiotics such as vancomycin or gentamicin loaded into the same cement. This contradicts the minimum inhibitory concentrations (MIC) values of AMPs and antibiotics against some bacterial strains obtained in standard in vitro assays. The formation of microbial biofilm on implants made from poly(methylmethacrylate)-based bone cement loaded with AMP was evaluated after the implants' removal from the infected bone sample. AMPs loaded in such model implants prevented microbial adhesion and subsequent formation of bacterial biofilm on their surface. Biofilms did form, on the other hand, on control implants made from the plain cement when these were implanted into the same infected bone sample. These results of the experiments performed in human bone tissue highlight the clinical potential of antimicrobial peptides for use in treating and preventing osteomyelitis caused by resistant pathogens.

Department of Orthopaedics 1st Faculty of Medicine Charles University Prague and University Hospital in Motol 5 Úvalu 84 150 06 Prague 5 Czech Republic

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences Flemingovo nám 2 166 10 Prague 6 Czech Republic

Zobrazit více v PubMed

Birt M.C., Anderson D.W., Toby E.B., Wang J. Osteomyelitis: Recent advances in pathophysiology and therapeutic strategies. J. Orthop. 2017;14:45–52. doi: 10.1016/j.jor.2016.10.004. PubMed DOI PMC

Nandi S.K., Bandyopadhyay S., Das P., Samanta I., Mukherjee P., Roy S., Kundu B. Understanding osteomyelitis and its treatment through local drug delivery system. Biotechnol. Adv. 2016;34:1305–1317. doi: 10.1016/j.biotechadv.2016.09.005. PubMed DOI

Winkler H., Haiden P. Treatment of chronic bone infection. Oper. Tech. Orthop. 2016;26:2–11. doi: 10.1053/j.oto.2016.01.002. DOI

Hanssen A.D., Osmon D.R., Patel R. Local antibiotic delivery systems: Where are we and where are we going? Clin. Orthop. Relat. Res. 2005;437:111–114. doi: 10.1097/01.blo.0000175122.50804.ce. PubMed DOI

Webb N.D., McCanless J.D., Courtney H.S., Bumgardner J.D., Haggard W.O. Daptomycin eluted from calcium sulfate appears effective against Staphylococcus. Clin. Orthop. Relat. Res. 2008;466:1383–1387. doi: 10.1007/s11999-008-0245-0. PubMed DOI PMC

Gálvez-López R., Peña-Monje A., Antelo-Lorenzo R., Guardia-Olmedo J., Moliz J., Hernández-Quero J., Parra-Ruiz J. Elution kinetics, antimicrobial activity, and mechanical properties of 11 different antibiotic loaded acrylic bone cement. Diagn. Microbiol. Infect. Dis. 2014;78:70–74. doi: 10.1016/j.diagmicrobio.2013.09.014. PubMed DOI

Jackson J., Leung F., Duncan C., Mugabe C., Burt H. The use of bone cement for the localized, controlled release of the antibiotics vancomycin, linezolid, or fusidic acid: Effect of additives on drug release rates and mechanical strength. Drug Deliv. Transl. Res. 2011;1:121–131. doi: 10.1007/s13346-011-0015-5. PubMed DOI

Webb J.C.J., Spencer R.F. The role of polymethylmethacrylate bone cement in modern orthopaedic surgery. J. Bone Jt. Surg. Br. 2007;89:851–857. doi: 10.1302/0301-620X.89B7.19148. PubMed DOI

Rouse M.S., Piper K.E., Jacobson M., Jacofsky D.J., Steckelberg J.M., Patel R. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J. Antimicrob. Chemother. 2006;57:301–305. doi: 10.1093/jac/dki435. PubMed DOI

Campoccia D., Montanaro L., Speziale P., Arciola C.R. Antibiotic-loaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use. Biomaterials. 2010;31:6363–6377. doi: 10.1016/j.biomaterials.2010.05.005. PubMed DOI

Arciola C.R., Campoccia D., Ehrlich G.D., Montanaro L. Biofilm-based implant infections in orthopaedics. Adv. Exp. Med. Biol. 2015;830:29–46. PubMed

Romano C.L., Toscano M., Romano D., Drago L. Antibiofilm agents and implant-related infections in orthopaedics: Where are we? J. Chemother. 2013;25:67–80. doi: 10.1179/1973947812Y.0000000045. PubMed DOI

Ribeiro M., Monteiro F.J., Ferraz M.P. Infection of orthopedic implants with emphasis on bacterial adhesion process and techniques used in studying bacterial-material interactions. Biomaterials. 2012;2:176–194. doi: 10.4161/biom.22905. PubMed DOI PMC

Brogden N.K., Brogden K.A. Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int. J. Antimicrob. Agents. 2011;38:217–225. doi: 10.1016/j.ijantimicag.2011.05.004. PubMed DOI PMC

Baltzer S.A., Brown M.H. Antimicrobial peptides—Promising alternatives to conventional antibiotics. J. Mol. Microbiol. Biotechnol. 2011;20:228–235. doi: 10.1159/000331009. PubMed DOI

Mishra B., Reiling S., Zarena D., Wang G. Host defense antimicrobial peptides as antibiotics: Design and application strategies. Curr. Opin. Chem. Biol. 2017;38:87–96. doi: 10.1016/j.cbpa.2017.03.014. PubMed DOI PMC

Yeaman M.R., Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003;55:27–55. doi: 10.1124/pr.55.1.2. PubMed DOI

Nguyen L.T., Haney E.F., Vogel H.J. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011;29:464–472. doi: 10.1016/j.tibtech.2011.05.001. PubMed DOI

Zhang L., Gallo R.L. Antimicrobial peptides. Curr. Biol. 2016;26:R14–R19. doi: 10.1016/j.cub.2015.11.017. PubMed DOI

Mishra B., Wang G. Individual and combined effects of engineered peptides and antibiotics on Pseudomonas aeruginosa biofilms. Pharmaceuticals. 2017;10:58. doi: 10.3390/ph10030058. PubMed DOI PMC

Faber C., Stallmann H.P., Lyaruu D.M., de Blieck J.M.A., Bervoets T.J.M., van Nieuw Amerongen A., Wuisman P.I.J.M. Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads. J. Antimicrob. Chemother. 2003;51:1359–1364. doi: 10.1093/jac/dkg258. PubMed DOI

Stallmann H.P., Faber C., Bronckers A.L.J.J., van Nieuw Amerongen A., Wuisman P.I.J.M. Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement. J. Antimicrob. Chemother. 2004;54:472–476. doi: 10.1093/jac/dkh346. PubMed DOI

Faber C., Hoogendoorn R.J.W., Stallmann H.P., Lyaruu D.M., van Nieuw Amerongen A., Wuisman P.I.J.M. In vivo comparison of Dhvar-5 and gentamicin in MRSA osteomyelitis prevention model. J. Antimicrob. Chemother. 2004;54:1078–1084. doi: 10.1093/jac/dkh441. PubMed DOI

Faber C., Stallmann H.P., Lyaruu D.M., Joosten U., von Eiff C., van Nieuw Amerongen A., Wuisman P.I.J.M. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant Staphylococcus aureus osteomyelitis model. Antimicrob. Agents Chemother. 2005;49:2438–2444. doi: 10.1128/AAC.49.6.2438-2444.2005. PubMed DOI PMC

Dijkshoorn L., Brouwer C.P.J.M., Bogaards S.J.P., Nemec A., van den Broek P.J., Nibbering P.H. The synthetic N-terminal peptide of human lactoferin, hLF(1-11), is highly effective against experimental infection caused by multidrug-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2004;48:4919–4921. doi: 10.1128/AAC.48.12.4919-4921.2004. PubMed DOI PMC

De Breij A., Riool M., Kwakman P.H.S., de Boer L., Cordfunke R.A., Drijfhout J.W., Cohen O., Emanuel N., Zaat S.A.J., Nibbering P.H., et al. Prevention of Staphylococcus aureus biomaterial-associated infections using a polymer-lipid coating containing the antimicrobial peptide OP-145. J. Control. Release. 2016;222:1–8. doi: 10.1016/j.jconrel.2015.12.003. PubMed DOI

Laverty G., Gorman S.P., Gilmore B.F. Antimicrobial peptide incorporated poly(2-hydroxyethyl methacrylate) hydrogels for the prevention of Staphylococcus epidermidis-associated biomaterial infections. J. Biomed. Mater. Res. Part A. 2012;100A:1803–1814. doi: 10.1002/jbm.a.34132. PubMed DOI

Čeřovský V., Buděšínský M., Hovorka O., Cvačka J., Voburka Z., Slaninová J., Borovičková L., Fučík V., Bednárová L., Votruba I., et al. Lasioglossins: Three novel antimicrobial peptides from the venom of the eusocial bee Lasioglossum laticeps (Hymenoptera: Halictidae) ChemBioChem. 2009;10:2089–2099. doi: 10.1002/cbic.200900133. PubMed DOI

Monincová L., Buděšínský M., Slaninová J., Hovorka O., Cvačka J., Voburka Z., Fučík V., Borovičková L., Bednárová L., Straka J., et al. Novel antimicrobial peptides from the venom of the eusocial bee Halictus sexcinctus (Hymenoptera: Halictidae) and their analogs. Amino Acids. 2010;39:763–775. doi: 10.1007/s00726-010-0519-1. PubMed DOI

Wang G., Li X., Wang Z. APD2: The updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res. 2009;37:D933–D937. doi: 10.1093/nar/gkn823. PubMed DOI PMC

Nešuta O., Buděšínský M., Hadravová R., Monincová L., Humpoličková J., Čeřovský V. How proteases from Enterococcus faecalis contribute to its resistance to short α-helical antimicrobial peptides. Pathog. Dis. 2017;75:ftx091. doi: 10.1093/femspd/ftx091. PubMed DOI

Wu Z., Ericksen B., Tucker K., Lubkowski J., Lu W. Synthesis and characterization of human α-defensins 4-6. J. Pept. Res. 2004;64:118–125. doi: 10.1111/j.1399-3011.2004.00179.x. PubMed DOI

Anderson R.J., Groundwater P.W., Todd A., Worsley A.J. Antibacterial Agents: Chemistry, Mode of Action, Mechanism of Resistance and Clinical Applications. 1st ed. John Wiley & Sons, Ltd.; Chichester, UK: 2012. pp. 308–313. Chapters 5.2.4–5.2.6.

Anderson R.J., Groundwater P.W., Todd A., Worsley A.J. Antibacterial Agents: Chemistry, Mode of Action, Mechanism of Resistance and Clinical Applications. 1st ed. John Wiley & Sons, Ltd.; Chichester, UK: 2012. pp. 158–161. Chapters 4.1.4–4.1.6.

Melicherčík P., Čeřovský V., Nešuta O., Jahoda D., Landor I., Ballay R., Fulín P. Testing the efficacy of antimicrobial peptides in the topical treatment of induced osteomyelitis in rats. Folia Microbiol. 2018;63:97–104. doi: 10.1007/s12223-017-0540-9. PubMed DOI

Hardouin P., Pansini V., Cortet B. Bone marrow fat. Jt. Bone Spine. 2014;81:313–319. doi: 10.1016/j.jbspin.2014.02.013. PubMed DOI

Polymer-Antimicrobial Peptide Constructs with Tailored Drug-Release Behavior